BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has long been a key player in the biotechnology sector, specializing in rare genetic diseases and innovative therapies. With a strong pipeline of treatments for conditions such as hemophilia, phenylketonuria (PKU), and dwarfism, the company has attracted significant attention from investors and analysts alike. However, as with any biotech stock,[…]